Clinical Scorecard: Acute Mania Induced by Lurasidone Treatment in a Patient with Bipolar I Disorder: A Case Study
At a Glance
Category
Detail
Condition
Key Mechanisms
Lurasidone acts as a dopamine D2 receptor antagonist and a serotonin 5-HT2A and 5-HT7 receptor antagonist, with partial agonist activity at 5-HT1A receptors, potentially leading to increased dopamine release and manic symptoms. Ensure this aligns with the source's detailed explanation.
Target Population
Care Setting
Key Highlights
Lurasidone can precipitate manic episodes in susceptible individuals.
The patient developed acute mania after lurasidone titration for bipolar depression.
Close monitoring is essential during treatment initiation and dosage adjustments.
The patient had a subtherapeutic serum valproate level at the time of lurasidone initiation.
Discontinuation of lurasidone and optimization of mood stabilizers led to symptom stabilization.
Ensure mood stabilizers are at therapeutic levels before initiating lurasidone.
Guideline-Based Recommendations
Diagnosis
Diagnosis of bipolar I disorder should consider prior manic episodes and current mood stabilization.
Management
Initiate lurasidone with caution in patients with a history of mania and ensure adequate mood stabilizer coverage.
Monitoring & Follow-up
Monitor for manic symptoms closely after initiating or increasing lurasidone dosage.
Risks
Risk of 'manic switch' with second-generation antipsychotics like lurasidone.
Patient & Prescribing Data
43-year-old male with a history of bipolar I disorder and recent severe depressive episode.
Lurasidone was titrated to 120 mg daily, leading to acute mania after one week.
Clinical Best Practices
Ensure mood stabilizers are at therapeutic levels before initiating lurasidone.
Educate patients and caregivers about the risks of manic episodes with antipsychotic treatment.
Implement a structured follow-up plan to monitor mood changes after treatment initiation, specifying frequency and methods.
